RARE - Ultragenyx Pharmaceutical Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
52.47
+0.92 (+1.78%)
As of 10:33AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close51.55
Open51.76
Bid51.96 x 900
Ask52.15 x 900
Day's Range51.45 - 52.72
52 Week Range37.44 - 90.98
Volume70,108
Avg. Volume577,865
Market Cap2.654B
Beta (3Y Monthly)3.59
PE Ratio (TTM)N/A
EPS (TTM)-4.00
Earnings DateFeb 18, 2019 - Feb 22, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est70.53
Trade prices are not sourced from all markets
  • J&J (JNJ) to Commence Pharma Q4 Earnings: What to Expect
    Zacksyesterday

    J&J (JNJ) to Commence Pharma Q4 Earnings: What to Expect

    J&J's (JNJ) Pharmaceuticals segment is likely to face difficult comparisons in fourth quarter.

  • Markit3 days ago

    See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.

    # Ultragenyx Pharmaceutical Inc ### NASDAQ/NGS:RARE View full report here! ## Summary * Bearish sentiment is moderate ## Bearish sentiment Short interest | Positive Short interest is moderate for RARE with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $2.84 billion over the last one-month into ETFs that hold RARE are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire7 days ago

    New Research Coverage Highlights Arthur J. Gallagher, Ultragenyx Pharmaceutical, Empire State Realty Trust, ConocoPhillips, Kilroy Realty, and NETGEAR — Consolidated Revenues, Company Growth, and Expectations for 2019

    NEW YORK, Jan. 11, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • ACCESSWIRE7 days ago

    Today's Research Reports on Trending Tickers: bluebird bio and Ultragenyx Pharmaceutical

    NEW YORK, NY / ACCESSWIRE / January 11, 2019 / U.S. markets finished in the green on Thursday, however gains were held back by a sharp decline in Macy’s shares that pressured retail stocks lower. The Dow ...

  • At biotech's big event, a chance for execs to shape LGBTQ diversity on boards
    American City Business Journals10 days ago

    At biotech's big event, a chance for execs to shape LGBTQ diversity on boards

    As corporate diversity issues are in the spotlight, a small group will assemble at the J.P. Morgan Healthcare Conference to build a network of current and potential LGBTQ board members.

  • American City Business Journals12 days ago

    JPM19 buzz-word bingo and the good, bad and ugly of biotech's big Union Square meetup

    From spotting buzz-words to scouting out prospective employers, here's our field guide for the 37th annual J.P. Morgan Healthcare Conference and the other events that collectively form JPM Week.

  • Outlook For Battered Biotech Stocks In 2019
    Investopedia12 days ago

    Outlook For Battered Biotech Stocks In 2019

    Biotech stocks, which have fallen 20% from last year's high based on the iShares Nasdaq Biotechnology ETF (IBB), could face more declines in the year ahead. A combination of negative headwinds including weak sales growth, earnings revisions and other forces are likely to plague the once-red hot sector.

  • This Biotech Stock Is Flying On Its Promising Gene Therapy
    Investor's Business Daily14 days ago

    This Biotech Stock Is Flying On Its Promising Gene Therapy

    Ultragenyx Pharmaceutical stock jumped Friday after its gene therapy showed promise in patients with an inherited disease that causes low blood sugar. The biotech studied three patients.

  • GlobeNewswire14 days ago

    Ultragenyx Announces Positive Topline Results from First Cohort of Phase 1/2 Clinical Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia

    Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced positive topline safety and efficacy data from the first, lowest dose cohort of the ongoing Phase 1/2 study of DTX401, an adeno-associated virus (AAV) based gene therapy for the treatment of glycogen storage disease type Ia (GSDIa). A biologic response, reflected by improved glucose control and increased time to hypoglycemia during fasting, was observed in all three patients, with two patients demonstrating a clinically meaningful improvement in time to hypoglycemia during a controlled fasting challenge.

  • Analysts Issue New Ratings on Large Health Care Stocks
    GuruFocus.com15 days ago

    Analysts Issue New Ratings on Large Health Care Stocks

    Several analysts started coverage of Moderna Inc. (MRNA), a biotechnology company that focuses on developing drugs based on messenger RNA. Goldman Sachs gave the stock a buy rating and established a price target of $25 per share. JPMorgan Chase initiated coverage with an overweight rating, setting a price target of $22.

  • GlobeNewswire15 days ago

    Ultragenyx to Present at J.P. Morgan Healthcare Conference

    The live and archived webcast of the company presentations will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases.

  • Markit29 days ago

    See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.

    # Ultragenyx Pharmaceutical Inc ### NASDAQ/NGS:RARE View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Positive Short interest is moderate for RARE with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding RARE are favorable, with net inflows of $2.20 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Hedge Funds Are Crazy About Ultragenyx Pharmaceutical Inc (RARE)
    Insider Monkeylast month

    Hedge Funds Are Crazy About Ultragenyx Pharmaceutical Inc (RARE)

    How do you pick the next stock to invest in? One way would be to spend hours of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

  • Markitlast month

    See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.

    # Ultragenyx Pharmaceutical Inc ### NASDAQ/NGS:RARE Score: Neutral (34) 1 day at current score. Upgraded from Negative on December 13th 2018 View full report here! ## Summary * This company ranked neutral compared to the Healthcare sector with only 2 positive IHS Markit Categories * Bearish sentiment is moderate * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Positive Short interest is moderate for RARE with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. ETFs that hold RARE had net inflows of $1.52 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and Ultragenyx Pharmaceutical

    NEW YORK, NY / ACCESSWIRE / December 13, 2018 / U.S. equities closed higher on Wednesday amidst renewed hopes over the U.S.-China trade talks. According to a report in Wall Street Journal, China is working ...

  • GlobeNewswirelast month

    Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita™ (burosumab injection) for the Treatment of X–linked Hypophosphatemia (XLH) in Adults and Children

    Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, Kyowa Hakko Kirin Co. Ltd, (Kyowa Hakko Kirin), and Kyowa Kirin International PLC (Kyowa Kirin International) today announced that Crysvita™ (burosumab injection) has been approved by Health Canada for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients one year of age and older. The product is expected to be available for prescription to Canadian patients in early 2019.

  • Ultragenyx (RARE) Down 7.2% Since Last Earnings Report: Can It Rebound?
    Zackslast month

    Ultragenyx (RARE) Down 7.2% Since Last Earnings Report: Can It Rebound?

    Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.

    Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of RARE earnings conference call or presentation 5-Nov-18 10:00pm GMT

    Q3 2018 Ultragenyx Pharmaceutical Inc Earnings Call

  • GlobeNewswire2 months ago

    Ultragenyx Announces Intent to Submit New Drug Application to U.S. FDA for UX007 for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Mid-2019

    NOVATO, Calif., Nov. 14, 2018 -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and.

  • See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.

    Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE

  • GlobeNewswire2 months ago

    Ultragenyx to Present at Upcoming Investor Conferences

    Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Credit Suisse Healthcare Conference on Wednesday, November 14, 2018 at 11:30 a.m. MT in Scottsdale, Arizona. Shalini Sharp, the company’s Chief Financial Officer, will present at the Piper Jaffray Healthcare Conference on Tuesday, November 27, 2018 at 11:30 a.m. ET in New York. Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases.

  • GlobeNewswire2 months ago

    Report: Exploring Fundamental Drivers Behind AcelRx Pharmaceuticals, Fossil Group, FMC, Ultragenyx Pharmaceutical, Shenandoah Telecommunications, and Marcus & Millichap — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Ultragenyx (RARE) Posts Narrower-Than-Expected Loss in Q3
    Zacks2 months ago

    Ultragenyx (RARE) Posts Narrower-Than-Expected Loss in Q3

    Ultragenyx (RARE) submitts regulatory filings in Canada, Brazil and Colombia for Crysvita for the treatment of XLH.

  • Amazon, Pandora, PTC Therapeutics, and More: Why These Stocks Are Trending
    Insider Monkey2 months ago

    Amazon, Pandora, PTC Therapeutics, and More: Why These Stocks Are Trending

    Although November 6 is very important to the stock market because it’s election day in the United States, traders are also paying attention to several equities that are trending for various reasons. Without further elaboration, let’s dive in and see why the spotlight is shining on Amazon.com Inc. (NASDAQ:AMZN), The Kraft Heinz Company (NASDAQ:KHC),  Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), PTC […]